Indications for ZELNORM:
Irritable bowel syndrome with constipation (IBS-C) in women <65yrs of age.
Limitations of Use:
Safety and effectiveness not established in men with IBS-C.
Take at least 30mins before a meal. 6mg twice daily. Discontinue after 4–6 weeks if inadequate control.
History of MI, stroke, TIA, or angina. History of ischemic colitis or other forms of intestinal ischemia. History of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions. Severe renal impairment (eGFR <15mL/min/1.73m2) or ESRD. Moderate to severe hepatic impairment (Child-Pugh B or C).
Cardiac ischemic events (including MACE). Assess for a history of cardiovascular disease and risk factors prior to therapy. Discontinue if MI, stroke, TIA, or angina occurs; evaluate risks/benefits for continued use. Discontinue and evaluate if ischemic colitis develops. Avoid use if experiencing frequent diarrhea. Discontinue if severe diarrhea, hypotension, or syncope occurs. Monitor for worsening of depression and emergence of suicidal thoughts/behaviors (esp. during initial months of treatment). Pregnancy. Nursing mothers: not recommended.
Selective 5-HT4 receptor agonist.
Headache, abdominal pain, nausea, diarrhea, flatulence, dyspepsia, dizziness.